Key Development
Imexpharm Pharmaceutical Joint Stock Company (Ticker: IMP)—a premier listed pharmaceutical manufacturer on the Vietnamese equity markets—has officially released its Board resolution appointing Mr. Liu Daping as the new Chairman of the Board of Directors for the remaining duration of the 2023–2027 corporate tenure. This structural leadership rotation follows the formal resignation of South Korean SK Group-affiliated board members, including Mr. Woo Sungmin and Mr. Chung Suyong.
This transfer of executive power is the direct consequence of a high-profile, 6 trillion VND (~$235 million) cross-border takeover bid executed at $57,400\text{ VND/share}$ by Lian SGP Holding Pte. Ltd., a captive subsidiary of China’s prominent Livzon Pharmaceutical Group. Concurrently with the executive overhaul, the Board finalized July 14, 2026, as the record date for its 2025 cash dividend deployment of 6% ($600\text{ VND/share}$), with disbursement scheduled for July 21, 2026.
Why It Matters
-
Transition from Korean Stewardship to Chinese Integration: The exit of SK Group and the arrival of Livzon Group marks a strategic inflection point for IMP. Moving away from a passive financial holding structure, IMP will now undergo deep operational integration into the raw active pharmaceutical ingredient (API) supply matrix and commercial portfolio of the mainland Chinese conglomerate.
-
Preserving Liquidity Consistency for Minority Shareholders: Maintaining the pre-scheduled 6% cash dividend distribution during a complete board restructuring signals excellent near-term liquidity stability and reinforces retail investor confidence in the new executive leadership.
-
Expanding Net Margins Amid Top-Line Volatility: IMP’s Q1 2026 financial reporting displays a clear operational divergence: net revenue contracted 8% year-on-year to 546 billion VND, yet net profit rose 10% to 82 billion VND. This demonstrates robust cost-containment efficiencies across selling, general, and administrative (SG&A) lines.
-
Establishing an Equity Floor Post-Market Correction: IMP stock currently trades around $41,200\text{ VND/share}$, down roughly 25% from its April high of over $55,000\text{ VND/share}$ (which reflected early M&A speculation). Livzon’s formal boarding and its previous institutional premium benchmark ($57,400\text{ VND/share}$) will function as a powerful valuation support mechanism for the asset through late 2026.
Healthcare Insight Analysis
From the perspective of Healthcare Insight, Livzon Pharmaceutical Group’s acquisition and its direct installation of Mr. Liu Daping as Board Chairman represents a textbook application of an “Upstream API Integration & Regional Infrastructure Capture” strategy deployed by mainland Chinese pharma majors targeting Southeast Asian hubs.
Imexpharm has long been recognized as the premium “antibiotics powerhouse” of Vietnam, boasting three manufacturing hubs housing 11 advanced production lines certified under rigorous European Good Manufacturing Practices (EU-GMP). This hardware moat awards IMP premium Group 1 and Group 2 classifications within public hospital tenders (ETC channel). However, the structural vulnerability for IMP—and the Vietnamese pharmaceutical sector broadly—rests on an over 90% reliance on imported foreign APIs, primarily routed from China and India, exposing gross margins to global raw chemical price volatility.
Livzon Pharmaceutical Group operates as a highly verticalized manufacturer commanding significant scale in small-molecule API synthesis, modern traditional Chinese medicine (TCM), and complex biologics. Consequently, absorbing IMP is not a passive portfolio investment; it is a highly calculated logistical masterstroke. Livzon is effectively transforming IMP into its dedicated, EU-GMP compliant manufacturing terminal in Southeast Asia. By routing proprietary, high-grade APIs directly from its mainland manufacturing sites to IMP’s facilities in Binh Duong and Dong Thap at cost, Livzon can drive down IMP’s manufacturing overheads, securing a near-unassailable pricing advantage during Vietnam’s centralized national hospital procurement cycles.
Concurrently, Livzon’s specialized next-generation therapeutic lines (targeting gastroenterology, cardiology, and neurology) can bypass prolonged regional R&D timelines via rapid tech-transfer initiatives onto IMP’s pre-certified production infrastructure, capturing high-margin chronic care segments without incurring exploratory regulatory drag.
Market Implications
-
For Domestic Manufacturers Competiting in the Hospital (ETC) Channel: The commercial alignment of IMP’s high-compliance EU-GMP infrastructure with Livzon’s verticalized cost-basis will exert heavy margin pressure on domestic generic peers such as Hau Giang Pharmaceutical (DHG), Pymepharco, and Cuu Long Pharmaceutical. Competing players will be forced to aggressively re-negotiate their own API sourcing frameworks to safeguard their positions in public sterile injectable tenders.
-
For Corporate Governance Dynamics and Procurement Re-Alignment: Shifting from the indirect portfolio oversight style of SK Group to the hands-on operational leadership of Chinese biopharma executives (Chairman Liu Daping and Board Member Liu Ning) will substantially accelerate commercial decision-making velocity. IMP’s global sourcing protocols will likely undergo thorough realignment to prioritize Livzon’s upstream chemical supply chain.
-
For the Inbound M&A Horizon of Vietnam’s Healthcare Assets: This multi-million-dollar transaction will spark matching inorganic target screening by Chinese, Japanese, and European aggregators hunting for remaining high-compliance pharmaceutical targets (such as Bidiphar, Traphaco, or companies possessing modular international facilities). Enterprise valuations for local pharma operators possessing validated international hardware will command persistent scarcity premiums.
Key Operational Metrics Ledger: Imexpharm (IMP)
| Operational & Financial Indicators | Metric Value | Strategic Sector Significance |
| Definitive Acquisition Valuation | ~6 Trillion VND ($57,400\text{ VND/share}$) | Livzon secures absolute corporate and board decision-making authority. |
| 2025 Deployed Cash Dividend Tactic | 6% nominal scale ($600\text{ VND/share}$) | Record Date: July 14, 2026 | Payment Execution: July 21, 2026. |
| Q1 2026 Consolidated Net Revenue | 546 Billion VND (Down 8% YoY) | Reflects temporary public tender slowdowns and restricted hospital intake cycles. |
| Q1 2026 Post-Tax Net Profit | 82 Billion VND (Up 10% YoY) | Confirms superior operational refinement and aggressive SG&A efficiency gains. |